Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Glandular Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm
Glandular Cell Neoplasm

Cancer Family

Glandular Cell Neoplasm

CI-CAN-00000188Explore in graph →

Non-malignant2,825 active trials43 approved drugs426 evidence items

NCIt: C7132

Overview
Statistics
Survival
Genomics166
Variants & evidence426
Drugs106
Trials10211
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (384)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 201–225 of 384 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.
· J Thorac Oncol · 2013 · PMID 23524406 · validated civic_curation pubmed
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
· J Thorac Oncol · 2013 · PMID 23584301 · validated civic_curation pubmed
Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations.
· J Thorac Oncol · 2016 · PMID 26724472 · validated civic_curation pubmed
A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.
· BMC Cancer · 2012 · PMID 23181703 · validated civic_curation pubmed
A novel K-ras mutation in colorectal cancer. A case report and literature review.
· Anticancer Res · 2009 · PMID 19661358 · validated civic_curation pubmed
Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).
· Jpn J Clin Oncol · 2010 · PMID 20522446 · validated civic_curation pubmed
RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.
· Cancer Discov · 2015 · PMID 26370156 · validated

Showing 201–225 of 384 publications

← Previous
1
…
8
9
10
…
16
Next →

civic_curation

Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.

· Lung Cancer · 2015 · PMID 25982012 · validated civic_curation pubmed

Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report.

· Onco Targets Ther · 2016 · PMID 27445490 · validated civic_curation pubmed

Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer.

· Ann Oncol · 2016 · PMID 27022066 · validated civic_curation pubmed

Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.

· J Thorac Oncol · 2016 · PMID 26845194 · validated civic_curation pubmed

Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature.

· Case Rep Oncol Med · 2015 · PMID 25692060 · validated civic_curation pubmed

MEN1 mutations in Hürthle cell (oncocytic) thyroid carcinoma.

· J Clin Endocrinol Metab · 2015 · PMID 25625803 · validated civic_curation pubmed

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.

· Ann Oncol · 2015 · PMID 26269204 · validated civic_curation pubmed

Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.

· PLoS One · 2016 · PMID 27045755 · validated civic_curation pubmed

Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer.

· Cancer Biol Ther · 2018 · PMID 27466707 · validated civic_curation pubmed

Association of GSTT1 non-null and NAT1 slow/rapid genotypes with von Hippel-Lindau tumour suppressor gene transversions in sporadic renal cell carcinoma.

· Pharmacogenetics · 2001 · PMID 11505222 · validated civic_curation pubmed

Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an EGFR-RAD51 Fusion.

· Oncologist · 2019 · PMID 31064887 · validated civic_curation pubmed

Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report.

· Gynecol Oncol Rep · 2019 · PMID 30809568 · validated civic_curation pubmed

Emerging a Novel VOPP1-EGFR Fusion Coexistent With T790M as an Acquired Resistance Mechanism to Prior Icotinib and Sensitive to Osimertinib in a Patient With EGFR L858R Lung Adenocarcinoma: A Case Report.

· Front Oncol · 2021 · PMID 35004270 · validated civic_curation pubmed

A Rare EGFR-SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib.

· Oncologist · 2020 · PMID 32162810 · validated civic_curation pubmed

Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR.

· Am J Surg Pathol · 2005 · PMID 15644781 · validated civic_curation pubmed

Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry.

· Clin Cancer Res · 2009 · PMID 19228722 · validated civic_curation pubmed

KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer.

· Cureus · 2016 · PMID 27004155 · validated civic_curation pubmed

Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report.

· Proc Natl Acad Sci U S A · 2016 · PMID 26917690 · validated civic_curation pubmed